![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 8, 5756-5766, February 22, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§,
**,
,
,
,
, and
§§
From the
Laboratory of Connective Tissues Biology,
Experimental Cancerology Research Center, Tour de Pathologie (B23/3),
University of Liège, B-4000 Liège, Belgium, the
¶ Laboratory of Protein Biochemistry and Protein Engineering,
University of Gent, K. L. Ledeganckstraat 35, 9000 Gent, Belgium,
the
Laboratoire de Biologie cellulaire et tissulaire, University
of Liège, 4020 Liège, Belgium, and the

Center for Gene Therapy, Tulane University
Health Sciences Center, New Orleans, Louisiana 70112
Received for publication, June 18, 2001, and in revised form, November 13, 2001
| |
ABSTRACT |
|---|
|
|
|---|
The processing of amino- and carboxyl-propeptides
of fibrillar collagens is required to generate collagen monomers that
correctly assemble into fibrils. Mutations in the ADAMTS2
gene, the aminopropeptidase of procollagen I and II, result in the
accumulation of non-fully processed type I procollagen, causing human
Ehlers-Danlos syndrome type VIIC and animal dermatosparaxis. In this
study, we show that the aminopropeptide of type I procollagen can be
cleaved in vivo in absence of ADAMTS-2 activity and that
this processing is performed at the cleavage site for ADAMTS-2. In an
attempt to identify the enzyme responsible for this alternative
aminoprocollagen peptidase activity, we have cloned the cDNA and
determined the primary structure of human and mouse ADAMTS-14, a novel
ADAMTS displaying striking homologies with ADAMTS-2 and -3. The
structure of the human gene, which maps to 10q21.3, and the mechanisms
of generation of the various transcripts are described. The existence
of two sites of initiation of transcription, in two different promoter
contexts, suggests that transcripts resulting from these two sites can
be differently regulated. The tissue distribution of ADAMTS-14, the regulation of the gene expression by various cytokines and the activity
of the recombinant enzyme are evaluated. The potential function of
ADAMTS-14 as a physiological aminoprocollagen peptidase in
vivo is discussed.
ADAMTS1 (A
Disintegrin and metalloprotease with
thrombospondin type I repeats) is a novel
family of metalloproteases found in vertebrates and invertebrates.
These enzymes are related to ADAMs as judged from sequence homology and
conserved domains such as a characteristic metalloprotease domain and a
disintegrin-like module. However, they differ from ADAMs by their
domain organization and the presence of distinct features. The most
specific hallmark is the presence of a central thrombospondin type I
repeat (TSPI) between the disintegrin-like module and the Cys-rich
domain. All ADAMTS, except ADAMTS-4, contain also TSPI-like domains in
varying numbers at the COOH terminus (1, 2). Currently, 12 ADAMTS from
vertebrates and a few from invertebrates (Drosophila and Caenorhabditis elegans) have been described (1, 2).
ADAMTS-1, -4, and -5 are able to cleave proteoglycans and are probably
involved in cartilage degradation during arthritis (3-5). ADAMTS-1 and -8 are potent anti-angiogenic molecules (6).
Adamts1 The primarily described activity of ADAMTS-2 is to excise the
aminopropeptide of type I and type II procollagens, explaining its
former trivial name aminoprocollagen I/II peptidase (9, 10). Removal of
the N- and C-propeptide of type I procollagen is required to generate
collagen monomers able to assemble into elongated and cylindrical
collagen fibers. Human Ehlers-Danlos type VIIC (dermatosparactic-type,
OMIM 225410) and animal dermatosparaxis are recessively inherited
disorders that are caused by mutations preventing the synthesis of
active ADAMTS-2 (11). As a consequence, pN-I collagen (type I collagen
that still contains the N- but not the C-propeptide) accumulates (12),
resulting in the polymerization of abnormal collagen fibers that appear
irregular, thin, branched and "hieroglyphic" in cross-section (13).
The main clinical feature of human patients and affected animals is a
severe cutaneous fragility. A similar phenotype has been recently
reported in transgenic mice with inactive alleles for
Adamts2 (14). Other type I collagen-rich tissues, such as
bone and tendon, do not seem to be functionally affected. Furthermore,
a significant proportion of type I collagen extracted from skin
biopsies of Ehlers-Danlos type VIIC (EDSVIIC) patients or from
dermatosparactic calves is NH2-terminal processed, at a
site that remained to be determined, although no active ADAMTS-2 is
synthesized (11). These observations and the fact that processing of
aminopropeptide is a complex event requiring a specific
three-dimensional native conformation (15) suggested that an enzyme
closely related to ADAMTS-2 would be responsible for this alternative
aminoprocollagen peptidase activity.
In this study, the specificity of the processing of the
aminopropeptide of type I collagen in absence of ADAMTS-2 is
demonstrated for the first time. The cloning of the cDNA and
characterization of human and mouse ADAMTS-14, a novel ADAMTS with
striking homologies with ADAMTS-2 and -3, are also reported. Finally,
the aminoprocollagen peptidase activity of the recombinant enzyme, the
structure of the gene, and the regulation of its expression are described.
Analysis of Procollagen Processing in Vivo--
For evaluating
the level of aminoprocollagen I (pNPI) processing in
Adamts2
The cleavage site of aminoprocollagen I in the absence of
Adamts-2 activity was determined on dermatosparactic calf
tendon. Collagen was purified from 1 M NaCl extracts by
sequential steps of precipitation and solubilization as described
earlier (16). The collagen preparation was then treated or not with
pyroglutamate aminopeptidase before electrophoresis on a pre-run 7.5%
acrylamide/piperazine diacrylamide gel in 50 mM Tris borate
buffer (pH 8.3) containing 0.1% SDS and 0.1 mM
thioglycolic acid. After transfer on a polyvinylidene difluoride
membrane (in 200 mM Tris borate, pH 9.5) and Coomassie Blue
staining, PCR Amplification and Sequencing of ADAMTS-14
cDNA--
Three large overlapping cDNA fragments covering the
ADAMTS14 cDNA sequence that corresponds to exons 2 to 22 of ADAMTS2 were PCR- amplified from fibroblasts cDNA
(37 cycles consisting of 94 °C for 30 s, 66 °C for 30 s, 72 °C for 90 s) using Taq DNA polymerase (Takara)
and three ADAMTS14 primer pairs
(5'-CTATGGTGTGACAGTGCCCTGCA-3' and 5'-GACGCTGCCCAGGCTGGTCTCA-3';
5'-GGCATGTGTCACCCCCTGAGGA-3' and 5'-TCCTTGTCACAGCCGACAGGCACA-3';
5'-GACGTGGTGTTCATGAACCAGGT-3' and 5'-GCCAGTGGGATGGCAGGGCACA-3'). PCR
products were then gel purified and sequenced using the manufacturers
recommended protocols (Thermo-sequenase radiolabeled terminator cycle
sequencing kit, Amersham Biosciences Inc.). To amplify mouse
Adamts14 cDNA, various human primer pairs were used. PCR
conditions were: 2 cycles consisting of 94 °C for 20 s,
50 °C for 20 s, and 72 °C for 1 min, followed by 35 cycles
consisting of 94 °C for 20 s, 66 °C for 20 s, and 72 °C for 1 min. PCR products amplified by
5'-CTATGGTGTGACAGTGCCCTGCA-3' and 5'-GACGCTGCCCAGGCTGGTCTCA-3' or
5'-AGCCTGGCCTACAAGTACGTCAT-3' and 5'- CTCTTCTTGTGGTCACACAGGTGT-3' pairs
were sequenced. The determination of partial mouse sequences allowed
the design a mouse-specific primer pair that was used to amplify and
sequence the central part of the murine cDNA.
For tissue distribution analysis, total RNA was purified from various
normal mouse tissues (17). Duplicate samples from 3 dilutions of RNA
from each tissue (10, 2, and 0.4 ng) were used for semi-quantitative
RT-PCR amplification.
Determination of the 5'-End of ADAMTS-14 cDNA--
The
5'-end of ADAMTS14 mRNA was amplified using the
FirstChoiceTM RLM-RACE Kit (Ambion) using the manufacturers
recommended protocols. Briefly, mRNA from cultured fibroblasts was
dephosphorylated and then treated with tobacco acid pyrophosphatase to
remove the cap structure from full-length mRNA, leaving a
5'-monophosphate. A RNA adapter was then ligated to the decapped
phosphorylated mRNA. After reverse transcription
(BcaBestTM RNA PCR kit, Takara), the 5'-end of the
ADAMTS14 cDNA was amplified using the sense "Outer
Adapter primer" from the kit and the ADAMTS14 5'-CCAGACACCACGTGGGAGAGGAA-3' antisense primer (30 cycles; 94 °C for
30 s, 64 °C for 30 s, 72 °C for 1 min). One microliter of the outer amplification product was then re-amplified using the
nested sense "Inner Adapter primer" and the
5'-CGTCCCCGAAAGTCTGTGCTGCA antisense primer (25 cycles; 94 °C for
30 s, 64 °C for 30 s, 72 °C for 1 min). Resulting PCR
products were then sequenced as described above.
Northern Analysis--
PCR amplified products generated from the
5'- or 3'-end of the ADAMTS14 cDNA (corresponding to
amino acids 153-471 and 824-1078, respectively) were cloned using
pCR4-TOPO cloning kit (Invitrogen) according to the manufacturers
protocols. Antisense labeled riboprobes were synthesized from 500 ng of
linearized plasmid (SpeI restriction site) using T7 RNA
polymerase (Strip-EZTM RNA kit, Ambion) and
[32P]UTP (ICN).
Messenger RNA purified from human skin fibroblasts in culture
(PolyATtractTM mRNA Isolation System III, Promega) was
separated by electrophoresis on a 0.9% agarose/formaldehyde gel and
transferred and fixed to a nylon membrane (Hybond N, Amersham
Biosciences, Inc.) by UV irradiation. The filters were then
sequentially prehybridized for 1 h (at 65 °C in 0.2 M NaH2PO4 (pH 7.2), 1 mM EDTA, 1% bovine serum albumin, 7% SDS, 20%
formamide), hybridized with labeled probes for 18 h (same
conditions as for prehybridization) and washed 3 times (at 65 °C in
40 mM NaH2PO4 (pH 7.2), 1 mM EDTA, 1% SDS) before autoradiographic exposure.
Semi-quantitative RT-PCR Assay--
The determination of
mRNA level by RT-PCR amplification requires the use of an internal
standard allowing to monitor the efficiency of each step of the
procedure in each sample. The construction of synthetic RNA standards
that are used as controls for RT-PCR quantification of various
mRNAs is described elsewhere (18). Briefly, we designed and
generated synthetic RNAs that have two main characteristics. First,
they can be RT-PCR amplified by using the same primer pairs used for
RT-PCR amplification of the cellular mRNAs. Second, their
amplification products are larger or smaller than those obtained from
the cellular mRNAs, enabling their discrimination by
electrophoresis when co-amplified in the same tube. Semi-quantification was obtained by calculating, for each sample, the ratio between the
level of the product generated from the endogenous mRNA and from a
defined copy number of the standard synthetic RNA. RT-PCR reactions
were performed, in a 25-µl reaction mixture, in an automated thermal
cycler (GeneAmp PCR System 2400 or 9600, PerkinElmer Life Sciences,
Norwalk, CT) using the GeneAmp Thermostable rTth Reverse Transcriptase
RNA PCR kit (PerkinElmer Life Sciences), 10 ng of total RNA, a known
copy number of internal standard RNA, when available, and specific
pairs of primers (5 pmol each). The various primer pairs allowed the
amplification of human
(5'-AGCCTGGCCTACAAGTACGTCAT-3'/5'-CTCTTCTTGTGGTCACACAGGTGT-3') or mouse
(5'-AGCCTGGCCTACAAGTACGTCAT-3'/5'-CTCCTCCACAGGCCTTGCTGCA-3') ADAMTS14 mRNA, human MMP1 mRNA
(5'-GAGCAAACACATCTGAGGTACAGGA-3'/5'- TTGTCCCGATGATCTCCCCTGACA-3') and
human (5'-GAACCATGAGGACGGCTTCTCCT-3'/5'-GGCTGCAGCGGGACCAGTGGAA-3') or
mouse (5'-CAGGCGCACACATAGTACCATCCA-3'/5'-CAGCCGCTACCTGCATTCCTATGA-3') ADAMTS2 mRNA. The RT step (70 °C for 15 s) was
followed by denaturation of RNA/DNA duplexes (95 °C for 2 min) and
by PCR amplification (adequate number of cycles consisting of 94 °C
for 15 s, 66 °C for 20 s, and 72 °C for 10 s).
RT-PCR products were resolved on a 10% polyacrylamide gel and analyzed
(Fluor-S-MultiImager, Bio-Rad) after staining (Gelstar, FMC BioProducts).
Effects of Cytokines and Growth Factors--
Human dermal
fibroblasts, at passages 4 to 12, were plated at a density of 8 × 103 cells/cm2 and cultured for 1 or 2 days in
Dulbecco's modified Eagle's medium (DMEM). The medium, supplemented
with 10% dialyzed and decomplemented FCS, contained or not
12-O-tetradecanoylphorbol-13-acetate (10 ng/ml), IL-1 Electron Microscopy--
Fragments of skin and tendon from wild
type and Adamts2 Recombinant ADAMTS-14--
An expression vector
containing the entire coding sequence of ADAMTS14 transcript
A (see "Results" section) and part of the 5'-untranslated
region was constructed. Briefly, 3 PCR products were amplified
(Pfu TurboTM DNA polymerase, Stratagene)
using cDNA from human skin fibroblasts in culture and three
different pairs of primers (1, 5'-CACACACAGCGGCCGCTTGCCCAGCCCGCGTCCCA-3' and 5'-
TGAAGAATTCGGTGCTGTCTGTGCGGATGA-3'; 2, 5'-CACAGAATTCTTCATTGAGCCTCTGGAGC-3' and
5'-CACAAAGCTTGAGAGCTCCTGCCTGCTT-3'; 3, 5'-CACAAAGCTTGTGCAGATCCCAGCAGGTGCCA-3' and 5'-
CTCTTCTAGATTAGCTAGCTGTCACCGGGGAGGCAGCAG-3'). By digestion with
appropriate restriction enzymes (1, NotI/EcoRI;
2, EcoRI/HindIII; 3, HindIII/NheI) and ligation of the PCR products, a
cDNA fragment covering the entire coding sequence was created in a
pCDNA4 vector (Invitrogen). A sequence verified full-length
insert was then cloned in the NotI/NheI sites
of a pCEP4 expression vector (Invitrogen) containing a modified
multiple cloning site and an additional sequence coding for a
"Flag" (DYKDDDDK) at the COOH terminus of the expressed recombinant
protein. This ADAMTS-14 expression vector, a similarly constructed
ADAMTS-2 vector2 and the
modified empty pCEP4 vector were then used for transfection of 293-EBNA
cells (Invitrogen) by electroporation (20 µg of plasmid; 220 V and
960 µF in 4-mm cuvettes). Stably transfected cells were then selected
in DMEM culture medium supplemented with 10% FCS and 200 µg/ml
hygromycin B.
For evaluating the production of recombinant ADAMTS-14, cells were
cultured at confluency, scraped, and rotated for 2 h at 4 °C in
an extraction buffer (50 mM Tris, pH 7.5, 200 to 500 mM NaCl, 2 mM CaCl2, 25 mM NEM, 1 mM phenylmethylsulfonyl fluoride). After centrifugation, the cell extracts were collected and the pellets
were solubilized in SDS-PAGE denaturation buffer containing 100 mM dithiothreitol. Conditioned culture medium and the two cell layer-associated fractions were then assayed by Western blotting by using the anti-FLAGTM M2 monoclonal antibody (Sigma) and
ECL Western blotting detection reagents (Amersham Biosciences
Inc.).
Aminoprocollagen Peptidase Activity of Recombinant
ADAMTS-14--
The stably transfected 293 cells amplified from two
separate transfections were grown to confluence in DMEM supplemented
with 10% FCS and hygromycin B (100 µg/ml). In some cultures, dextran sulfate (average Mr 500,000; 0.01%) or
concanavalin A (10 or 50 µM) were added for the last
48 h of culture. Cells were then scraped and extracted as
described above. Aliquots of cell extracts were then stored at 4 °C
or incubated in presence of p-aminophenylmercuric acetate
(0.3 mM for 15 min at 25 °C) or trypsin (100 µg/ml for 15 or 30 min at 37 °C) followed by an incubation with soybean trypsin inhibitor (500 µg/ml for 5 min at 37 °C). The various samples of cell extracts were then assayed for their aminoprocollagen peptidase activity using 14C-labeled pNI collagen as
described earlier (10). Values determined for the cell transfected with
the empty vector were considered as background and substracted from
values obtained for cells expressing recombinant ADAMTS-2 or -14. Aminoprocollagen peptidase activity of ADAMTS-14 are reported in % of
the ADAMTS-2 activity.
Co-culture experiments were performed in DMEM supplemented with 10%
FCS and ascorbic acid (50 µg/ml) in the absence of hygromycin B. Stably transfected 293 cells were plated with a similar number of skin
fibroblasts isolated from normal or dermatosparactic calf. After
24 h, the culture medium was changed and
L-[2,3-3H]proline (45 Ci/mmol, 10 µCi/ml)
was added. After 24 h, the culture mediums and the cell layers
were collected separately. The collagen polypeptides were recovered
from the cell layer by extraction at 4 °C with 0.1 M
acetic acid and from the culture medium by differential salt
precipitation with ammonium sulfate as described earlier (16). The
pattern of labeled collagen polypeptides was analyzed by 6.25%
SDS-PAGE in nonreducing conditions and visualized after fluorography.
Procollagen Processing in Dermatosparaxis--
The level of type I
aminoprocollagen (pNI) processing in the skin of wild type (WT) or
Adamts2
The specificity of the processing of pNI collagen in the absence of
Adamts-2 activity was assessed by amino acid sequencing of
the NH2 terminus of processed Identification of ADAMTS-14 cDNA and
Gene--
Based upon the hypothesis that the specific aminoprocollagen
peptidase activity observed in animals lacking Adamts-2
results from the expression and the activity of a closely related
enzyme, we scanned nucleic acid data bases from GenBankTM
using the human ADAMTS2 cDNA sequence (accession number
AJ003125). Besides homologies with ADAMTS2 and
ADAMTS3 cDNA and genes (on chromosome 5 and 4, respectively), homology was also found between portions of exons 6, 7, 8, and 10 of ADAMTS2 and sequences from chromosome 10 (accession numbers: AC069538, AC016043, AC007484, AC018979, and
AL358817). A second homology search using less stringent parameters and
the sequence of individual ADAMTS2 exons revealed that, with
the exception of exons 1, 5, and 21, each ADAMTS2 exon had
partial sequence homology with sequences in chromosome 10. This
suggested the existence of a gene coding for a new ADAMTS
closely related to ADAMTS2.
By RT-PCR, we found that this new ADAMTS gene was actually
expressed in human skin fibroblasts in culture and in placenta, although at a lower level. Region of the mRNA corresponding to exons 2 to 22 of ADAMTS2 was then RT-PCR amplified and
sequenced. This allowed to determine that sequences corresponding to
exons 5 and 21 of ADAMTS2 were present in the new ADAMTS but
displayed very low homology, explaining why they were not detected by
scanning of the data bases. We also found an alternative splicing
mechanism leading to the removal of the last 9 bases of exon 6 (Table
I). The ADAMTS14 name was
assigned to this new cDNA, in agreement with the Human Gene
Nomenclature Committee (GenBankTM accession number
AF366351). Comparison of the ADAMTS14 cDNA sequence with
the draft sequence of the human genome revealed that the gene is
located on chromosome 10 (q21.3). The exon/intron structure has been
determined (Table I). A 5'-RACE method was used for the determination
of sequences located upstream exon 2. Two different sequences were
identified. They represent 2 alternative exons 1 that were named exon
1A and 1B (Fig. 3, Table I). Comparison with genomic sequences showed that the beginning of exon 1B (5'-TATTT) starts at a tctgTATTT potential Cap signal located 17 base
pairs (bp) downstream a potential TATA-box (tgtatat) (19). This
suggests that the TATTT sequence represents the actual start of
transcription of this transcript. For exon 1A, the 5'-end sequence that
was determined (TTGC) does not start after a typical Cap site, perhaps suggesting that the actual 5' end of the transcript had not been cloned. A tcagc Cap signal 27 bp upstream and adequately preceded (82 bp) by a typical GC-box could be the actual start of transcription. As
a confirmation of the presence, at the 5' end of the mRNA, of the
alternative exons 1A and 1B, we performed a RT-PCR assay using a common
antisense primer specific of exon 2 and one sense primer specific of
exon 1A or exon 1B. Products of the expected size (204 and 241 bp,
respectively) and sequence were obtained. However, another product
(±700 bp) was also RT-PCR amplified using the exon 1B-specific primer.
In absence of the RT step, this product was not detected, demonstrating
that it did not result from the amplification of genomic DNA.
Sequencing revealed that this product was generated from a large exon,
named 1C, consisting of exon 1B, intron 1B, and exon 2 fused together
(Fig. 3, Table I). In the following, the mRNA beginning with exon
1A, 1B, or 1C will be named transcript A, B, or and C, respectively.
RT-PCR evaluation of the relative level of the three transcripts in
cultured fibroblasts revealed that transcript A is more abundant than
transcript C that is much more abundant than B. Moreover, while
transcript A is expressed in placenta, skin, and fibroblasts,
transcripts B and C are found at a significant level only in
fibroblasts (not shown).
Primary Structure of ADAMTS-14--
For transcript A, the most
5'in-frame ATG found in exon 1A (Fig. 3) is located in a conserved
Kozak consensus sequence (20). Its use as a Start codon would lead to
the presence of a moderately hydrophobic NH2-terminal
domain (amino acid 52 to 76) that could serve as a signal peptide (Fig.
4A). Low homology was found
between part of this sequence and the NH2 terminus of
ADAMTS-2 (amino acids 42 to 59). For transcripts B and C, the first ATG
triplets that are found are not in a perfectly conserved Kozak
consensus sequence and are followed by Stop codons. The first ATG in a
suitable Kozak motif for translation (A at position
A partial mouse sequence was also determined. It showed a high
similarity with human ADAMTS-14, mainly in regions supposed to be
critical for enzyme function such as the furin cleavage site, the
metalloprotease domain and the beginning of TSPI (Fig. 4A).
Northern Analysis--
As seen for other ADAMTS genes,
ADAMTS14 mRNA was expressed at low level. Therefore,
Northern analysis was performed on mRNA from fibroblasts in
culture, the richest source of ADAMTS14 mRNA, using
antisense riboprobe to increase the sensitivity of the assay. Two
different probes were used, specific of either the 5' end or the 3' end
of the mRNA. The 5' end probe revealed two transcripts of about 4.5 and 5.7 kb (Fig. 5), which is similar to
the size of other ADAMTS transcripts. The 3' specific probe
recognized these two products too but also smaller transcripts (about
2.8, 2.0, and 1.1 kb).
Tissue Distribution and Regulation of
Expression--
Tissue-specific expression was evaluated by RT-PCR.
Adamts14 is expressed in all examined tissues, with highest
levels in type I collagen-rich tissues and in fibroblasts in culture
(Fig. 6). Lower levels were observed in
liver, stomach, brain, and eye. This tissue distribution and the
relative amount of Adamts14 mRNA are quite similar to
those determined for Adamts2 (21), the only exception being
the eye which has a low Adamts14 expression while it
contains a high level of Adamts2. Scanning EST data bases using human and mouse cDNA sequences revealed that
ADAMTS14 is also expressed in ovary (accession numbers:
BF906533, BF906528, and BF906335), kidney tumor (accession number
BF823025), and mammary tumor (accession number BF123774) and that it is up-regulated in larynx carcinoma (accession number AJ403134).
Regulation of expression of ADAMTS14 mRNA was
investigated in culture treated with factors known to be regulators of
the expression of various genes in fibroblast (Fig.
7). As a control for the efficiency of
cell treatment, MMP1 expression was also measured in the
various conditions. Results are expressed as a ratio of the values
determined for treated on untreated cells. Modulation of
MMP1 expression measured in the different conditions was in good agreement with previous reports (22, 23) confirming the efficiency
of cell treatment. At the opposite, none of the five treatments was
able to significantly modify the ADAMTS14 overall expression
(Fig. 7), neither that of individual transcripts A, B, and C (not
shown). Similar results were obtained for ADAMTS2 and
-3 (not shown).
Recombinant ADAMTS-14 Analysis--
Recombinant ADAMTS-14 with a
COOH-terminal FLAG epitope was produced in 293-EBNA cells stably
transfected with an eukaryotic expression vector containing the
full-length ADAMTS14 cDNA. Cell populations were also
created by transfection of, respectively, the empty vector and an
ADAMTS-2 expression vector. As ADAMTS-2, ADAMTS-14 was not detected in
the conditioned culture medium (not shown) but could be efficiently
recovered from the cell layer, in the absence of detergent, using mild
conditions of extraction such as Tris buffer containing 0.2 M NaCl. This suggests that the recombinant ADAMTS-14 is
secreted but can be immobilized at the cell surface or in the
extracellular matrix. By Western blotting, the recombinant ADAMTS-14
appears as a single band displaying a molecular size slightly higher
than expected from the deduced amino acid sequence, suggesting that it
is glycosylated (Fig. 8). The
aminoprocollagen peptidase activity of recombinant ADAMTS-14 recovered from cell extracts was assayed and compared with the activity
of cells containing the empty vector (background values) or recombinant
ADAMTS-2, as a positive control. In the absence of any treatment, the
activity of ADAMTS-14 was barely detectable suggesting either that this
enzyme is not an aminoprocollagen peptidase or that it is secreted in
an inactive pro-form. Various treatments known to promote the
activation of pro-metalloproteases were performed. Limited trypsin
digestion of recombinant ADAMTS-14 increased its aminoprocollagen
peptidase activity with values ranging from 3 to 13% of the activity
determined in similar conditions for ADAMTS-2 (Fig.
9A). At the opposite,
p-aminophenylmercuric acetate had no significant effect.
When cell cultures were treated for 2 days in the presence of dextran
sulfate or concanavalin A, the aminoprocollagen peptidase activity
recovered from the extracts was also significantly increased (Fig.
9B). The activity of ADAMTS-14 was also investigated, in the
absence of exogenous activation, in a co-culture model. For these
experiments, control 293 cells or 293 cells expressing ADAMTS-2 or -14 were plated with fibroblasts isolated from dermatosparactic calf skin.
In culture, 80% of the type I collagen polypeptides secreted by these fibroblasts still contain the amino-terminal propeptide (pN An intriguing observation in Ehlers-Danlos type VIIC (EDSVIIC)
patients and animal dermatosparaxis is the presence of processed type I
collagen in the absence of a functional ADAMTS-2 (12). This observation
was confirmed in this study by using
Adamts2 ADAMTS14 cDNA Cloning--
By scanning data bases, homology
was found between ADAMTS2 cDNA and sequences located on
chromosome 10 (q21.3) that could represent exons of a new
ADAMTS gene. After confirmation, by RT-PCR, that this
potential novel gene can be expressed as mRNA, the complete sequence of human ADAMTS14 cDNA (name assessed in
agreement with Human Gene Nomenclature Committee) and also part of the
Adamts14 mouse ortholog were determined by sequencing
overlapping RT-PCR fragments and 5'-RACE products. Different
transcripts are expressed from the gene. An alternative splicing
mechanism occurring at the end of exon 6 leads to an in-frame deletion
of 9 bases (Table I). Only the 9-base skipped form is found in mouse,
while in ADAMTS2 the corresponding 9 bases are always
present, suggesting that this alternative splicing does not have a
major biological significance. The presence of three different exons 1, named 1A, 1B, and 1C (Table I, Fig. 3), was also determined. Exon 1A on one hand and exon 1B or 1C on the other hand resulted from the alternative use of two different signals of initiation of transcription (Fig. 3). The difference between transcripts B and C (Fig. 3) is the
presence in transcript C of a sequence that is spliced (intron 1B)
during the maturation of transcript B. As a result, exon 1C is a large
exon (1064 bp) consisting of sequences that correspond on transcript B
to exon 1B, intron 1B, and exon 2. Another example of such a large
first exon is found in the ADAMTS1 gene, where exon 1 is
1136 bp long (25). The existence of 2 sites of initiation of
transcription, in two different promoter contexts, suggests that
transcripts resulting from these two sites can be differently
regulated. Preliminary data support this hypothesis, indicating that
transcript A is expressed at relatively high level in skin, placenta,
and human fibroblasts in culture while transcripts B and C are found at
significant levels in fibroblasts only. Northern analysis showed a
4.5-kilobase pair major product. This size is similar to the size of
other ADAMTS mRNA and is consistent with the cDNA sequence that
was determined. The larger product of about 5.7 kilobase pairs probably
results from the alternative use of a more 3' polyadenylation signal.
The origin of the three smaller transcripts, identified with the
3'-specific probe only, is still unknown. Determination of their
mechanism of generation will require fine mapping of gene products with
a set of smaller probes. Existence of transcripts lacking either 5' or
3' sequences is not unique in the ADAMTS family and have been
determined for ADAMTS23
(11). The physiological significance of
these truncated transcripts remains to be elucidated. A puzzling
observation is the presence, on Northern blot, of only one band in the
4.5-kilobase pair region while, from RT-PCR data, we would expect to
see two bands: one from transcript C and a smaller for transcript A
(489 bases shorter), transcript B being expressed at a too low level to
be seen on Northern blot. Two hypotheses could explain these apparently
contradictory observations. Since quantification of transcripts A and C
does not use the same primer pair, we cannot exclude that differences in the efficiency of the two assays would have led to biased results, a
transcript being actually relatively much more expressed, compared with
the other, than expected from RT-PCR quantification. According to this
hypothesis, only this transcript would be visible by Northern analysis,
the two others being undistinguishable from the background. Another
explanation is that exon 1A is longer than the 135 bp reported on Table
I. Evaluation of its size is based upon the presence in genomic DNA of
a suitable CAP signal situated 27 bp upstream the ADAMTS14
cDNA sequence determined by 5'-RACE. If, instead, exon 1A extends a
few hundred bases upstream, the size of transcripts A and C would be
too close to be discriminated on Northern blot.
Adamts14 Regulation of Expression--
The highest levels of
Adamts14 were found in collagen-rich tissue, supporting its
role as an aminoprocollagen peptidase. However, significant levels were
also detected in all tissues investigated, such as brain, spleen, and
liver, indicating that Adamts-14 may have other functions.
Similar findings have been reported for ADAMTS-2 (14). As
ADAMTS2 and -3,3 ADAMTS14
is not transcriptionally regulated in fibroblasts by various soluble
factors. At the opposite, ADAMTS1 is an inflammatory associated gene (25) that can be induced by IL-1 (26). Up-regulation of
the expression of ADAMTS12 by transforming growth factor ADAMTS-14 Primary Structure--
Determination of the ADAMTS-14
primary structure requires the determination of the translation start
site. For transcript A, the most 5' in-frame ATG in a suitable Kozak
consensus sequence is found in exon 1A (Fig. 3). This ATG codon would
result in the synthesis of a polypeptide displaying a moderately
hydrophobic sequence at its NH2 terminus, which could serve
as a signal peptide (Fig. 4A). Homology existing between
this sequence (amino acids 42 to 61) and the sequence derived from exon
1 of ADAMTS2 or from mouse Adamts14 suggests the
actual use of this ATG as a start of translation. For transcripts B and
C, the first suitable ATG corresponds to Met68 of the
protein synthesized from transcript A (Figs. 3 and 4A). As a
result, ADAMTS-14 polypeptides from transcripts B and C do not contain
an obvious signal peptide. It remains to be determined whether these
ADAMTS-14 variants are secreted, as all the ADAMTS described so far, or
sequestered in the cytoplasm.
Besides differences at the NH2 terminus, ADAMTS-14 variants
are identical and display very high homology with ADAMTS-2 and -3, in
terms of length of polypeptide chain, primary structure, and domains
organization. The highest similarity was observed around the catalytic
site and the lowest, as expected, in the pro-domain and the
COOH-terminal tail (Fig. 4). These results indicate that ADAMTS-2, -3, and -14 are three members of a structurally and functionally distinct
subfamily of ADAMTS proteases. It has recently been demonstrated that
ADAMTS-3, as ADAMTS-2, can process pN-II collagen (28). Because of the
high homology between these three enzymes, it was conceivable that
ADAMTS-14 may also display aminoprocollagen peptidase activity and may
be the enzyme responsible for pN-I collagen maturation in tissues of
dermatosparactic calves, Adamts2
In summary, the gene structure and the primary structure of mouse and
human ADAMTS-14 have been determined. The tissue distribution of this
novel ADAMTS, its homology with ADAMTS-2 and -3, and its aminoprocollagen peptidase activity, which was demonstrated in vitro using fibroblasts lacking ADAMTS-2 activity, suggest its participation in procollagen processing in vivo. Various
transcripts have been identified. They result from the use of two
different promoters and transcription start sites and lead to the
synthesis of ADAMTS-14 isoforms that differ by their amino terminus.
These observations suggest complex mechanisms of regulation of gene expression and enzyme function. Creation of
Adamts14
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
mice display abnormal growth,
defective fertility, and altered organ morphology and function (7). A
C. elegans Adamts, gon-1, was found essential for gonadal
morphogenesis (8). Both the metalloprotease domain and some TSPI-like
repeats are required for the control of this process.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
mice (14), various organs and
tissues were ground at liquid nitrogen temperature and extracted with
0.1 M acetic acid for 18 h at 4 °C. After
centrifugation, the supernatants were neutralized and ammonium sulfate
was added (40% saturation). After centrifugation (8000 × g, 30 min), the pellets were washed in an ammonium sulfate solution (20% saturation) and finally dissolved in 0.1 M
acetic acid. After precipitation at 33% ethanol (final concentration) at neutral pH, the pellets containing collagen were denatured in
Laemmli sample buffer. Similar amounts of protein were separated by
electrophoresis on a 7.5% SDS-PAGE and stained with Coomassie Blue.
1I and
2I bands were collected and submitted to 6 cycles of Edman degradation amino acid sequencing.
(100 units/ml), tumor necrosis factor-
(5 ng/ml), epidermal growth
factor (20 ng/ml), or transforming growth factor-
(5 ng/ml). Total
RNA was purified using the High Pure RNA Isolation kit (Roche Molecular
Biochemicals).
/
mice were fixed for 60 min
at room temperature in 2.5% glutaraldehyde in 0.1 Sörensen's
buffer (pH 7.4), postfixed for 30 min in 0.1% osmium tetroxide in
Sörensen's buffer, dehydrated in a series of ethanol
concentrations and embedded in epoxy resin (Epon 812, Fluka). Ultrathin
sections were stained with uranyl acetate and lead citrate before being
examined using a Jeol electron microscope CX100 II at 60 kV.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
mice was investigated by SDS-PAGE
(Fig. 1A). Only
1 and
2
chains were observed in tissues of WT mice, illustrating the complete processing of the aminopropeptide of type I collagen. In
Adamts2
/
mice, pN
1I and pN
2I chains
were detected, as expected from an animal lacking Adamts-2
activity. However, mature
1 and
2 chains were present, suggesting
the existence of an alternative aminoprocollagen peptidase activity.
Similar observations were made in bovine dermatosparaxis and human
Ehlers-Danlos syndrome type VIIC (12). The level of processing varied
from tissue to tissue (Fig. 1B) and was not related to the
collagen content in the various organs. Skin contains mostly
unprocessed pNI-collagen (60 to 70%) while, in tendon, it represents
only 20 to 25%. When most of the pN-I collagen is not processed, such
as in the skin of Adamts2
/
mice, collagen
fibers are deeply altered (Fig. 2,
compare panels A and B). On the opposite, in
tendons, where a high proportion of collagen is correctly processed,
fibers look almost normal in terms of diameter, shape, and
supramolecular organization (Fig. 2, panels C and
D). Their mechanical resistance is also normal (not
shown).

View larger version (24K):
[in a new window]
Fig. 1.
Accumulation of pN
1
and pN
2 type I collagen in mouse tissues.
A, the pattern of type I collagen polypeptide purified from
skin and tendon of "wild type" (WT) and
Adamts2
/
(TS2
/
) mice was
determined after SDS-PAGE and Coomassie Blue staining. In WT, only
1
and
2 mature chains are visible. In TS2
/
, absence of
Adamts-2 activity results in the accumulation of pN
1 and
pN
2 chains. Higher proportions of pNI
chains were observed in
skin. B, type I collagen was extracted from various tissues
of TS2
/
mice. After electrophoresis on SDS-PAGE and
staining, pN
1, pN
2,
1, and
2 type I collagen bands were
quantified. For each tissue, the proportion of pN
chains is
expressed as a percentage of total type I collagen. Mu,
muscle; Ki: kidney; He, heart;
Lu, lung; St, stomach; Ey, eye;
Bo, bone; Te, tendon; Sk, skin.

View larger version (145K):
[in a new window]
Fig. 2.
Structure of collagen fibrils. Collagen
fibrils from skin and tendons of wild type (WT) and
Adamts2
/
(TS2
/
) mice were
observed by electron microscopy. In TS2
/
, skin collagen
fibrils are strongly disorganized while they display an almost normal
shape in tendon. Bars represent 0.3 µm. Top
panels, collagen fibrils (longitudinal and cross-section) in skin
from a WT mouse (A) or a TS2
/
mouse
(B). Bottom panels, collagen fibrils, in
longitudinal (C) or cross (D) section, in tendon
from a TS2
/
mouse.
1 and
2 chains isolated
from dermatosparactic calf tendon. A first attempt failed to provide sequence information, suggesting that their amino terminus was blocked,
possibly by modification of the glutamine residue which is the first
expected amino acid of
1 and
2 when the processing occurs at the
site normally cleaved by Adamts-2. After digestion with
pyroglutamate aminopeptidase, a LSYGYD sequence was obtained for the
1 chain and a FDAKGG sequence for the
2 chain. In bovine type I
collagen, these two sequences immediately follow the Gln residue
in position 1 of correctly processed
1 and
2. These features
demonstrate that, even in absence of Adamts-2 activity in vivo, procollagen processing can occur at the cleavage
site for Adamts-2.
ADAMTS14 gene structure

View larger version (18K):
[in a new window]
Fig. 3.
Mechanisms of generation of alternative exon
1A (A), 1B (B), and 1C
(C). Open rectangles representing
exons and lines representing promoter or intronic sequences
are not at scale. Dotted lines illustrate splicing
mechanisms. For transcript A, exon 1A is joined to exon 2 by splicing
of intron 1A. A potential regulatory GC-box is located upstream the
5'-end of the transcript as determined by 5'-RACE. The ATG triplet
located in exon 1A in a suitable Kozak consensus sequence is indicated.
Transcripts B and C start 17 bp downstream a potential TATA-box. Intron
1B is spliced during the maturation of transcript B while it is
conserved in transcript C. The first potential ATG start codon for
these two transcripts is located in the sequence corresponding to exon
2 of transcript B. The size of E1A is a minimal size evaluated from the
presence in genomic DNA of a suitable CAP signal situated 27 bp
upstream the cDNA sequence determined by sequencing of 5'-RACE
products. The use of a more upstream CAP signal would lead to a larger
E1A.
3 and G at
position +4, with respect to the A (+1) of the ATG Start codon) is
found in exon 2 (Fig. 3). The predicted protein from these transcripts starts at Met68 of the sequence reported for transcript A
(Fig. 4A) and does not contain an obvious signal peptide.
Besides this difference, the predicted proteins translated from the
three transcripts are identical. They have a higher homology with
ADAMTS-2 and -3 than with the other ADAMTS (Fig. 4B) and
they display a similar domains organization consisting of a pro-domain
separated from the metalloprotease domain by a furin cleavage site, a
disintegrin-like domain, a central TSPI, a cystein-rich domain,
a spacer domain, three additional TSPI, and a COOH-terminal tail
without significant homology for ADAMTS-2 or -3, except for a highly
conserved PLAC domain (Fig. 4A). Analysis of the sequence of
the catalytic site and the first TSPI, two of the most conserved
domains in the ADAMTS family, confirmed that ADAMTS-14 is closely
related to ADAMTS-2 and -3. Specific hallmarks of these three enzymes
are a Thr and a Glu at position 3 and 10 of the catalytic site and Phe
(+9), Lys/Arg (+21) and Arg (+23) of the first TSPI (Fig.
4B).

View larger version (52K):
[in a new window]
Fig. 4.
Human and mouse ADAMTS-14 amino acid sequence
and structure. A, the human sequence (hTS14) is
reported on the middle lines. The beginning and end ([ ])
of the partial mouse sequence (mTS14) and human ADAMTS-2 (hTS2) are
reported on the upper or lower lines,
respectively, but only at positions where their sequence differs from
hTS14. The peptide sequence translated from transcript A only is in
italics (amino acids 1 to 67). The MQG-(369-371) sequence
is alternatively present due to alternative splicing mechanism at the
end of exon 6. In the mouse these three amino acids are always absent.
The furin cleavage site (RKRR), the catalytic site and Met turn, the
PLAC domain and the 4 TSPI are underlined. The start of the
disintegrin-like, the Cys-rich, and Spacer domains are indicated (
).
B, the catalytic domain and the first TSPI module of the
ADAMTS family members were compared. Length of the different members
and their degree of similarity with ADAMTS-14 are reported between
parentheses. Amino acid residues identical to those in
ADAMTS-14 are shaded. Residues that are hallmarks of
ADAMTS-2, -3, and -14 are indicated (*).

View larger version (28K):
[in a new window]
Fig. 5.
Northern analysis of ADAMTS14
transcripts. The size of the RNA markers is shown on the
left. mRNA from skin fibroblasts in culture was
separated on an agarose/formaldehyde gel and transferred onto a nylon
membrane. Blots were revealed using labeled cRNA probes specific either
for the 5'-end (lane 1) or the 3'-end (lane 2) of
the ADAMTS14 mRNA.

View larger version (8K):
[in a new window]
Fig. 6.
Distribution pattern of Adamts14
in mouse tissues. Duplicate samples containing 10, 2, or 0.4 ng of total RNA purified from various tissues were RT-PCR amplified
using specific primers for Adamts14 and 28 S RNA. After
electrophoresis on 10% polyacrylamide gel and staining, the amplified
cDNA products were quantified. Values obtained with 28 S primers
were equivalent in all tissues (not shown). Values measured for
products amplified from Adamts14 mRNA are reported as
arbitrary units of absorbance per ng of total RNA in the samples.
Br, brain; He, heart; St, stomach;
Li, liver; In, intestine; Mu, muscle;
Ey, eye; Bo, bone; Sk, skin;
Lu, lung; Sp, spleen; Ki, kidney;
Te, tendon; Fb, fibroblasts in culture.

View larger version (21K):
[in a new window]
Fig. 7.
Regulation of ADAMTS14
expression. Fibroblasts in culture were left untreated or
were treated for 1 day (black bar) or 2 days (gray
bar) with 12-O-tetradecanoylphorbol-13-acetate (5 ng/ml), IL-1
(IL-1, 100 units/ml), tumor necrosis factor-
(TNF,
10 ng/ml), epidermal growth factor (20 ng/ml), or transforming growth
factor
(TGF, 5 ng/ml). MMP1 (A) and
ADAMTS14 (B) mRNA levels were assayed by
RT-PCR. Results are expressed as the ratio of mRNA levels in
treated/untreated control cultures.
chains) due to the absence of ADAMTS-2 activity (Fig.
10, lane 1). Co-culture of
these deficient fibroblasts with 293 cells transfected with the empty
vector did not modify the level of processing. By contrast, the
presence of 293 cells expressing ADAMTS-2 resulted in a complete cleavage of the pN
chains similar to that observed with normal calf
skin fibroblasts (Fig. 10, lanes 3 and 6),
validating this co-culture model for the evaluation of aminoprocollagen
peptidase activity. When 293 cells expressing ADAMTS-14 were used, a
significant conversion of both pN
chains into
chains was
observed (Fig. 10, lanes 4 and 5). A
quantification of the polypeptides pattern indicated that the relative
level of
chains rose from 20 to 52% in the presence of ADAMTS-14,
evidencing its aminoprocollagen peptidase activity.

View larger version (33K):
[in a new window]
Fig. 8.
Western blotting analysis of the recombinant
ADAMTS-14. 293 cells stably transfected with the empty vector
(Cont.) or an ADAMTS-14 expression vector (TS14)
were scraped and extracted for 2 h at 4 °C in a Tris buffer
containing 0.5 M NaCl. An aliquot of the extract was
migrated on SDS-PAGE and analyzed by Western blotting using an
anti-FLAG antibody.

View larger version (28K):
[in a new window]
Fig. 9.
Aminoprocollagen peptidase activity of
recombinant ADAMTS-14 in vitro. A, cells stably
transfected with the empty vector, with an ADAMTS-2 expression vector
or an ADAMTS-14 expression vector (two independent transfections) were
grown to confluence in DMEM supplemented with 10% FCS. Cell layers
extracts (performed in a buffer containing 0.2 M NaCl) were
left untreated (
), or were incubated with trypsin for 15 (
) or 30 min (
) or with p-aminophenylmercuric acetate
(APMA) for 15 min (
) before determination of the
aminoprocollagen peptidase activity. Values obtained with cells
containing the empty vector were considered as background and
substracted from the other measurements. Activities of ADAMTS-14 are
reported in % of activities determined for ADAMTS-2 under identical
assay conditions. B, the same cells as in A were
grown in DMEM supplemented with 10% FCS. 48 h before confluency,
culture medium was removed and replaced by fresh medium containing 10%
FCS only (
), 10% FCS and dextran sulfate at 0.01% (
), or 10%
FCS and concanavalin A at 10 (
) or 50 (
) µM. Cell
extracts were not treated and immediately investigated for their
aminoprocollagen peptidase activity as described in A.

View larger version (34K):
[in a new window]
Fig. 10.
Processing of aminoprocollagen type I in
co-culture. Skin fibroblasts from dermatosparactic (DF)
or normal (NF) calf were cultivated, in DMEM supplemented
with 10% FCS and ascorbic acid (50 µg/ml), alone (lanes 1 and 6), or with a similar number of 293 cells containing the
empty vector (cont, lane 2), an ADAMTS-2
expression vector (TS-2, lane 3), or an ADAMTS-14
expression vector (cell populations resulting from two separate
transfections, lanes 4 and 5). After a 24-h
labeling with L-[2,3-3H]proline, the pattern
of type I collagen polypeptides secreted in the culture medium was
visualized after SDS-PAGE and autoradiography. pN
1 and
pN
2,
1 and
2 collagen chains that contain the
amino-terminal propeptide;
1 and
2, fully matured type I collagen
polypeptides.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
mice. The level of processed
collagen varied from tissue to tissue and could not be correlated to
type I collagen content. For example, 80% of type I collagen is
processed in tendon while only 30 to 40% is processed in the skin.
This difference is biologically significant since, in
Adamts2
/
mice, tendon has a normal
mechanical resistance and contains almost normal collagen fibers while
the skin is highly fragile and contains the abnormal hyeroglyphic
collagen polymers seen in dermatosparactic calf and EDSVIIC patients
(12, 13). Studies investigating the processing of pN-I collagen in
ADAMTS-2 deficient human and animal had been performed so far by
analysis of a SDS-PAGE pattern. Hence, it remained to be determined
that the observed processing occurred at the cleavage site specific for
ADAMTS-2 or at a close site. For example, MMP13 can cleave the
aminotelopeptide of type I collagen (24), generating collagen fragments
of about the same size as the products released from ADAMTS-2
digestion. Sequencing of processed
1 and
2 chains extracted from
dermatosparactic calf tendon demonstrated that pN-I cleavage occurred
at the bonds that are cleaved by ADAMTS-2
(Pro142-Glu143 for
1 and
Ala79-Glu80 for
2). Processing of pN-I
collagen requires a complex three-dimensional structure of the
substrate in which the 3 propeptides (two
1 and one
2) are folded
back across the major triple helix of the molecule (15). This specific
requirement and the fact that the processing occurs at the ADAMTS-2
cleavage site for both
1 and
2 chains in dermatosparactic animal
strongly suggested that a closely related enzyme could display a true
aminoprocollagen peptidase activity. Because of its high homology with
ADAMTS-2, ADAMTS-3 was first considered as the enzyme that could
partially compensate for the ADAMTS-2 deficiency. Preliminary
investigations on tissue distribution and relative level of
ADAMTS3 were performed to verify this hypothesis (not
shown). ADAMTS3 is expressed only at low levels in many
organs. In addition, no correlation was observed between the proportion
of processed type I collagen in the tissues of
Adamts2
/
mice and the relative level of
Adamts3. These data suggested that an enzyme other than
Adamts-2 or -3 could display aminoprocollagen peptidase activity.
(2) and of aggrecanases (ADAMTS4 and -5) by IL-1,
IL-6, and tumor necrosis factor-
is also reported (27).
/
mice, and
EDSVIIC patients. Preliminary data were in favor of this hypothesis.
For example, highest ADAMTS14 mRNA levels were detected
in collagen-rich tissues. In addition, the mRNA levels of
ADAMTS14 and ADAMTS2 were similar, suggesting
that the amount of ADAMTS-14 enzyme is high enough to allow maturation
of significant amounts of pN-I collagen. Finally, the eye of
Adamts2
/
mice, where Adamts14 is
barely expressed, contained very low levels of processed type I
collagen. The suspected aminoprocollagen peptidase activity of
ADAMTS-14 was evaluated using recombinant enzyme. When produced by 293 cells grown in culture medium supplemented with fetal calf serum alone,
recombinant ADAMTS-14 did not display any activity. However, upon
limited digestion of the latent enzyme with trypsin or when recombinant
ADAMTS-14 was extracted from cells cultivated in conditions known to
promote metalloprotease activation (29, 30), significant
aminoprocollagen peptidase activity was evidenced. These results were
further confirmed in a co-culture model. In these experiments,
aminoprocollagen type I (pN
1 and pN
2 chains) synthesized by
dermatosparactic calf skin fibroblasts were significantly processed
into mature
chains in the presence of cells producing ADAMTS-14.
Together, these results suggest that ADAMTS-14 could be the enzyme
responsible for the aminoprocollagen type I processing activity in the
absence of ADAMTS-2. They indicate also that ADAMTS-14 is synthesized as a latent enzyme that requires activation to display aminoprocollagen peptidase activity. Generation of active ADAMTS-14 in co-culture demonstrates that this activation can occur extracellularly and probably results from enzymatic activity associated with fibroblasts. This activation is not performed in 293 cells cultivated in basal culture conditions suggesting a specific, possibly cell type-regulated, mechanism. Such a tissue-regulated mechanism of activation is also
suspected for ADAMTS-2 since this enzyme is expressed at high levels in
some tissues (heart, kidney, and muscle) that are poor in type I
collagen and from which no significant aminoprocollagen peptidase
activity can be extracted (21). The existence of a cell type-regulated
activation of ADAMTS-14 would also explain why dermatosparactic skin
and tendon, which express similar levels of ADAMTS-14, contain a
different proportion of fully processed type I collagen. According to
this hypothesis, ADAMTS-14 produced in fibroblasts would be only poorly
processed into an active aminoprocollagen peptidase while the
activation process would be much more efficient in tendon. This will be
evaluated, in further studies, by expressing recombinant ADAMTS-14 in
fibroblasts from dermatosparactic skin and tendon using an adenoviral
vector, the only one procedure allowing significant synthesis of
recombinant protein in almost every primary fibroblasts.
/
mice, and eventually their
breeding with Adamts2
/
mice, is planned to
unravel other functions of ADAMTS-14 and to evaluate potential overlaps
in the role of these two closely related enzymes.
| |
ACKNOWLEDGEMENTS |
|---|
The skillful technical assistance of Y. Goebels, A. Heyeres, M.-J. Nix, and G. Rega is acknowledged.
| |
FOOTNOTES |
|---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF366351.
§ Research associate of the Belgian Fonds National de la Recherche Scientifique and supported by Belgian National Fonds National de la Recherche Scientifique Grant 1.5.131.01 and the Fonds Special pour la Recherche Grant 1165003.
** Research associate of the Belgian Fonds National de la Recherche Scientifique.
§§ To whom correspondence should be addressed: Laboratory of Connective Tissues Biology, Tour de Pathologie (B23/3), University of Liège, B-4000 Liège, Belgium. Tel.: 32-4-3662456; Fax: 32-4-3662457; E-mail: LCTB@ulg.ac.be.
Published, JBC Papers in Press, December 7, 2001, DOI 10.1074/jbc.M105601200
2 A. Colige, C. M. Lapière, and B. V. Nusgens, manuscript in preparation.
3 A. Colige, personal observation.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: ADAMTS, A disintegrin-like and metalloprotease with thrombospondin type I repeats; EDS, Ehlers-Danlos syndrome; RT, reverse transcription; FCS, fetal calf serum; TSPI, thrombospondin type I repeat; pN collagen, procollagen that still contains the amino- but not the carboxyl-propeptide; DMEM, Dulbecco's modified Eagle's medium; IL, interleukin; RACE, rapid amplification of cDNA ends.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Tang, B. L. (2001) Int. J. Biochem. Cell Biol. 33, 33-44[CrossRef][Medline] [Order article via Infotrieve] |
| 2. |
Cal, S.,
Argüelles, J. M.,
Fernandez, P. L.,
and López-Otin, C.
(2001)
J. Biol. Chem.
276,
17932-17940 |
| 3. |
Tortorella, M. D.,
Burn, T. C.,
Pratta, M. A.,
Abbaszade, I.,
Hollis, J. M.,
Liu, R.,
Rosenfeld, S. A.,
Copeland, R. A.,
Decicco, C. P.,
Wynn, R.,
Rockwell, A.,
Yang, F.,
Duke, J. L.,
Solomon, K.,
George, H.,
Bruckner, R.,
Nagase, H.,
Itoh, Y.,
Ellis, D. M.,
Ross, H.,
Wiswall, B. H.,
Murphy, K.,
Hillman, M. C., Jr.,
Hollis, G. F.,
Newton, R. C.,
Magolda, R. L.,
Trazaskos, J. M.,
and Arner, E.
(1999)
Science
284,
1664-1666 |
| 4. |
Abbaszade, I.,
Liu, R. Q.,
Yang, F.,
Rosenfeld, S. A.,
Ross, O. H.,
Link, J. R.,
Ellis, W. M.,
Tortorella, M. D.,
Pratta, M. A.,
Hollis, J. M.,
Wynn, R.,
Duke, J. L.,
George, H. J.,
Hillman, M. C., Jr,
Murphy, K.,
Wiswall, B. H.,
Copeland, R. A.,
Decicco, C. P.,
Bruckner, R.,
Nagase, H.,
Itoh, Y.,
Newton, R. C.,
Magolda, R. L.,
Trazaskos, J. M.,
Hollis, G. F.,
Arner, E.,
and Burn, T. C.
(1999)
J. Biol. Chem.
274,
23443-23450 |
| 5. | Kuno, K., Okada, Y., Kawashima, H., Nakamura, H., Miyazaki, M., Ohno, H., and Matsushima, K. (2000) FEBS Lett. 478, 241-245[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Vázquez, F.,
Hastings, G.,
Ortega, M.-A.,
Lane, T. F.,
Oikemus, S.,
Lombardo, M.,
and Iruela-Arispe, M. L.
(1999)
J. Biol. Chem.
274,
23349-23357 |
| 7. | Shindo, T., Kurihara, H., Kuno, K., Yokoyama, H., Wada, T., Kurihara, Y., Imai, T., Wang, Y., Ogata, M., Nishimatsu, H., Moriyama, N., Oh-hashi, Y., Morita, H., Ishikawa, T., Nagai, R., Yazaki, Y., and Matsushima, K. (2000) J. Clin. Invest. 105, 1345-1351[Medline] [Order article via Infotrieve] |
| 8. | Blelloch, R., and Kimble, J. (1999) Nature 399, 586-590[CrossRef][Medline] [Order article via Infotrieve] |
| 9. |
Lapière, C. M.,
Lenaers, A.,
and Kohn, L.
(1971)
Proc. Natl. Acad. Sci. U. S. A.
68,
3054-3058 |
| 10. |
Colige, A.,
Beschin, A.,
Samyn, B.,
Goebels, Y.,
Van Beeumen, J.,
Nusgens, B. V.,
and Lapière, C. M.
(1995)
J. Biol. Chem.
270,
16724-16730 |
| 11. | Colige, A., Sieron, A. L., Li, S.-W., Schwarze, U., Petty, E., Wertelecki, W., Wilcox, W., Krakow, D., Cohn, D. H., Reardon, W., Byers, P. H., Lapière, C. M., Prockop, D. J., and Nusgens, B. V. (1999) Am. J. Hum. Genet. 63, 308-317 |
| 12. | Nusgens, B. V., Verellen-Dumoulin, G., Hermans-Le, T., De, Paepe, A., Nuytinck, L., Piérard, G. E., and Lapière, C. M. (1992) Nat. Genet. 1, 214-217[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Piérard, G. E., and Lapière, C. M. (1976) J. Invest. Dermatol. 66, 2-7[Medline] [Order article via Infotrieve] |
| 14. | Li, S.-W., Arita, M., Fertala, A., Bao, Y., Kopen, G. C., Långsjö, T. K., Hyttinen, M. M., Helminen, H. D., and Prockop, D. J. (2001) Biochem. J. 355, 271-278[CrossRef][Medline] |